IBDEI1BD ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22338,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,22338,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,22339,0)
 ;;=D63.8^^87^981^22
 ;;^UTILITY(U,$J,358.3,22339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22339,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,22339,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,22339,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,22340,0)
 ;;=C22.3^^87^981^26
 ;;^UTILITY(U,$J,358.3,22340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22340,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,22340,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,22340,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,22341,0)
 ;;=D61.9^^87^981^27
 ;;^UTILITY(U,$J,358.3,22341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22341,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,22341,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,22341,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,22342,0)
 ;;=D56.1^^87^981^29
 ;;^UTILITY(U,$J,358.3,22342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22342,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,22342,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,22342,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,22343,0)
 ;;=C83.79^^87^981^31
 ;;^UTILITY(U,$J,358.3,22343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22343,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,22343,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,22343,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,22344,0)
 ;;=C83.70^^87^981^32
 ;;^UTILITY(U,$J,358.3,22344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22344,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,22344,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,22344,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,22345,0)
 ;;=D09.0^^87^981^39
 ;;^UTILITY(U,$J,358.3,22345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22345,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,22345,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,22345,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,22346,0)
 ;;=D06.9^^87^981^40
 ;;^UTILITY(U,$J,358.3,22346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22346,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,22346,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,22346,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,22347,0)
 ;;=D06.0^^87^981^42
 ;;^UTILITY(U,$J,358.3,22347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22347,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,22347,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,22347,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,22348,0)
 ;;=D06.1^^87^981^43
 ;;^UTILITY(U,$J,358.3,22348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22348,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,22348,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,22348,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,22349,0)
 ;;=D06.7^^87^981^41
 ;;^UTILITY(U,$J,358.3,22349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22349,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,22349,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,22349,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,22350,0)
 ;;=D04.9^^87^981^44
 ;;^UTILITY(U,$J,358.3,22350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22350,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,22350,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,22350,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,22351,0)
 ;;=C91.11^^87^981^47
 ;;^UTILITY(U,$J,358.3,22351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22351,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,22351,1,4,0)
 ;;=4^C91.11
